Respiratory Syncytial Virus Infections/mortality; Respiratory Syncytial Virus Infections/prevention & control; Respiratory Syncytial Virus Vaccines/immunology; Respiratory Syncytial Viruses/immunology; Respiratory Syncytial Viruses/pathogenicity; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized/administration & dosage; Antibodies, Monoclonal, Humanized/immunology; Antibodies, Monoclonal, Humanized/therapeutic use; Antibodies, Neutralizing/immunology; Antibodies, Viral/immunology; COVID-19 Vaccines; Child, Preschool; Clinical Trials, Phase III as Topic; Drug Approval; Female; Humans; Immunity, Maternally-Acquired/immunology; Infant; Infant, Newborn; Inflammation/immunology; Pregnancy; Respiratory Syncytial Virus Infections/immunology; Respiratory Syncytial Virus Infections/virology; Respiratory Syncytial Virus Vaccines/adverse effects; Respiratory Syncytial Virus Vaccines/chemistry; Respiratory Syncytial Viruses/chemistry; Viral Fusion Proteins/chemistry; Viral Fusion Proteins/immunology; Viral Fusion Proteins/metabolism; Virus Internalization; mRNA Vaccines/administration & dosage; mRNA Vaccines/immunology

Industry; Vaccines; Virology